<DOC>
	<DOCNO>NCT00840671</DOCNO>
	<brief_summary>It show Cerebrolysin combination Alteplase , medication recover blood flow brain , effective save medication treat ischeamic stroke .</brief_summary>
	<brief_title>Combined Treatment With Alteplase ( Rt-PA ) CerebrolysinÂ® Acute Ischemic Hemispheric Stroke</brief_title>
	<detailed_description>The current trial evaluate combine treatment use Cerebrolysin immediately thrombolysis guarantee neurotrophic component able reach endanger brain area efficiently . An early start treatment guarantee rescue neuron reduce overall damage.The study follow design pure thrombolytic trial investigate , early neuroprotective treatment Cerebrolysin able improve overall outcome patient day 90 evaluation visit . Due initial finding special emphasis also put analyse speed recovery .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Fibrinolytic Agents</mesh_term>
	<mesh_term>Cerebrolysin</mesh_term>
	<criteria>Female male inpatient . Age : 1880 year . If female , patient must pregnant Clinical diagnosis ischemic stroke cause measurable neurological deficit define impairment language , motor function , cognition and/or gaze , vision neglect . Ischemic stroke defined event characterize sudden onset acute focal neurologic deficit presume due cerebral ischemia CT scan excludes haemorrhage . Onset symptom within 3 hour prior initiation rtPA administration . Stroke symptoms present least 30 minute significantly improve treatment . Symptoms must distinguishable episode generalize ischemia ( i.e . syncope ) , seizure migraine disorder . Patient willing participate voluntarily sign write patient inform consent . Informed consent obtain patient subject 's legally authorize representative relative , defer applicable , accord regulatory legal requirement participate country . Patients unable sign able understand mean participation study may give oral witness informed consent . These patient make clear undoubtful willing participate voluntarily must able understand explanation content information sheet . A write consent obtain soon possible . Willingness ability comply protocol . Evidence intracranial haemorrhage ( ICH ) CTscan Violation inclusion criterion approve clinical study director study safety officer Failure perform evaluate screen baseline examination Hospitalisation ( except study purpose ) change concomitant medication 4 week prior screen screen period Participation another therapeutic clinical trial 3 month baseline Patients history prior stroke concomitant diabetes Prior stroke within last 3 month Platelet count 100x103/mm3 Blood glucose &lt; 50 &gt; 400 mg/dl ( &lt; 2.77 &gt; 22.15 mmol/L ) Known haemorrhagic diathesis Manifest recent severe dangerous bleed Known bacterial endocarditis , pericarditis Acute pancreatitis Documented ulcerative gastrointestinal disease last 3 month , oesophageal varix , arterialaneurysm , arterial/venous malformation Neoplasm increase bleed risk Severe liver disease , include hepatic failure , cirrhosis , portal hypertension , oesaphageal varix ) active hepatitis Major surgery significant trauma past 3 month Lab value seriously abnormal , and/or 2 lab value abnormal approve clinical study director study safety officer Serious drug allergy Hypersensitivity one component drug Severe renal impairment Systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg , aggressive management ( IV medication ) necessary reduce BP limit Recent ( less 10 day ) traumatic external heart massage , obstetrical delivery , recent puncture noncompressible bloodvessel ( e.g . subclavian jugular vein puncture ) Chronic intoxication chronic substance use disorder pharmaceutical , drug , alcohol industrial poison Symptoms ischemic attack begin 3 hour prior start thrombolytic therapy time symptom onset unknown Minor neurological deficit symptom rapidly improve start infusion Severe stroke assess clinically ( e.g . NIHSS &gt; 25 ) and/or appropriate imaging technique Epilepsy epileptic seizure onset stroke Symptoms suggestive subarachnoid haemorrhage , even CTscan normal Known history suspect intracranial haemorrhage Suspected subarachnoid haemorrhage condition subarachnoid hemorrhage aneurysm Any history central nervous system damage ( i.e . neoplasm , aneurysm , intracranial spinal surgery ) Haemorrhagic retinopathy , e.g . diabetes ( vision disturbance may indicate haemorrhagic retinopathy ) Administration heparin within previous 48 hour thromboplastin time exceed upper limit normal laboratory Patients receive oral anticoagulant , e.g . warfarin sodium Special attention give possible additive effect use conjunction antidepressant MAOinhibitors Cerebrolysin mix balance amino acid solution infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Cerebrolysin</keyword>
	<keyword>Alteplase</keyword>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Modified Rankin Scale</keyword>
	<keyword>NIH Stroke Scale</keyword>
	<keyword>Barthel Index</keyword>
	<keyword>Glasgow Outcome Score</keyword>
</DOC>